Recent discoveries of the prevalence of inactivating mutations in the acetyltransferase genes EP300 and CREBBP in lymphomas have highlighted the crucial role of epigenetics in the pathobiology of lymphomas, including especially DLBCL [3, 4]. The gene discussed is CREBBP; the disease is diffuse large B-cell lymphoma.